Non‑invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG‑PET/CT and CT

Otani,Tamaki; Kondo,Kazuya; Takizawa,Hiromitsu; Kajiura,Koichiro; Fujino,Haruhiko; Otsuka,Hideki; Miyoshi,Hirokazu

doi:10.3892/or.2018.6818

Non‑invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG‑PET/CT and CT

Authors:
- Tamaki Otani
- Kazuya Kondo
- Hiromitsu Takizawa
- Koichiro Kajiura
- Haruhiko Fujino
- Hideki Otsuka
- Hirokazu Miyoshi
View Affiliations

Affiliations: Radioisotope Research Center, Tokushima University Graduate School, Tokushima City, Tokushima 770‑8503, Japan, Department of Oncological Medical Services, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima City, Tokushima 770‑8503, Japan, Department of Thoracic, Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima City, Tokushima 770‑8503, Japan, Department of Medical Imaging/Nuclear Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima City, Tokushima 770‑8503, Japan
Published online on: October 24, 2018 https://doi.org/10.3892/or.2018.6818
Pages: 447-454

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We established patient‑like models of lung cancer metastasis by orthotopically implanting human non‑small cell lung cancer cell lines into SCID mice. We evaluated the utilities of small‑animal computed tomography (CT) and positron‑emission tomography‑computed tomography (PET/CT) in these models to non‑invasively and repeatedly monitor the anticancer effects of cisplatin and erlotinib. We orthotopically implanted three non‑small cell lung cancer cell lines, A549, FT821 and PC‑9, into SCID mice. These mice were then divided into three groups: Control, cis‑diamminedichloroplatinum (II) (CDDP) (7‑mg/kg CDDP, single administration intraperitoneally), and erlotinib (25 mg/kg erlotinib/day, oral administration 5 days/week). After treatment initiation, we repeatedly performed PET/CT and CT measurements and assessed anticancer effects based on tumor volumes and FDG uptake. A549 tumors were not affected by CDDP or erlotinib. FT821 tumors were highly responsive to CDDP. PC‑9 tumors, which have an epidermal growth factor receptor mutation, were highly responsive to erlotinib. Histological results and metastatic rates correlated with the anticancer effects shown by CT. In our orthotopic SCID mouse lung cancer models, 18FDG‑PET/CT and CT imaging non‑invasively and repeatedly monitored the efficacies of cisplatin and erlotinib against not only implanted tumors, but also mediastinal lymph node metastases.

View Figures

View References

1	Stinchcombe TE, Bogart J, Veeramachaneni NK, Kratzke R and Govindan R: Annual review of advances in non-small cell lung cancer research: A report for the year 2010. J Thorac Oncol. 6:1443–1450. 2011. View Article : Google Scholar : PubMed/NCBI
2	Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, et al: National Cancer Institute SEER cancer statistics review. 1975-2006, http://seer.cancer.gov/csr/1975_2006November. 2009
3	Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
4	Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
5	Francia G, Cruz-Munoz W, Man S, Xu P and Kerbel RS: Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 11:135–141. 2011. View Article : Google Scholar : PubMed/NCBI
6	Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 133:571–573. 1889. View Article : Google Scholar
7	Wilmanns C, Fan D, O'Brian CA, Bucana CD and Fidler IJ: Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer. 52:98–104. 1992. View Article : Google Scholar : PubMed/NCBI
8	Fidler IJ: Models for spontaneous metastasis. Cancer Res. 66:97872006. View Article : Google Scholar : PubMed/NCBI
9	Peterson JK and Houghton PJ: Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer. 40:837–844. 2004. View Article : Google Scholar : PubMed/NCBI
10	Miyoshi T, Kondo K, Ishikura H, Kinoshita H, Matsumori Y and Monden Y: SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells. Anticancer Res. 20:161–163. 2000.PubMed/NCBI
11	Ishikura H, Kondo K, Miyoshi T, Kinoshita H, Hirose T and Monden Y: Artificial lymphogenous metastatic model using orthotopic implantation of human lung cancer. Ann Thorac Surg. 69:1691–1695. 2000. View Article : Google Scholar : PubMed/NCBI
12	Ishikura H, Kondo K, Miyoshi T, Kinoshita H, Takahashi Y, Fujino H and Monden Y: Suppression of mediastinal metastasis by uracil-tegafur or cis-diamminedichloroplatinum(II) using a lymphogenous metastatic model in a human lung cancer cell line. Clin Cancer Res. 7:4202–4208. 2001.PubMed/NCBI
13	Fujino H, Kondo K, Miyoshi T, Ishikura H, Takahashi Y, Sawada N, Hirose Y, Takizawa H, Nagao T, Sakiyama S, et al: Establishment of patient-like SCID mouse model by orthotopically implanting primary cultured cells from surgically-resected lung cancer tissues. Oncol Rep. 10:1709–1715. 2003.PubMed/NCBI
14	Fujino H, Kondo K, Ishikura H, Maki H, Kinoshita H, Miyoshi T, Takahashi Y, Sawada N, Takizawa H, Nagao T, et al: Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer. Mol Cancer Ther. 4:1409–1416. 2005. View Article : Google Scholar : PubMed/NCBI
15	Takizawa H, Kondo K, Toba H, Kenzaki K, Sakiyama S and Tangoku A: Fluorescence diagnosis of lymph node metastasis of lung cancer in a mouse model. Oncol Rep. 22:17–21. 2009.PubMed/NCBI
16	Sauter AW, Spira D, Schulze M, Pfannenberg C, Hetzel J, Reimold M, Klotz E, Claussen CD and Horger MS: Correlation between [¹⁸F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 40:677–684. 2013. View Article : Google Scholar : PubMed/NCBI
17	Walker CM, Chung JH, Abbott GF, Little BP, El-Sherief AH, Shepard JA and Lanuti M: Mediastinal lymph node staging: From noninvasive to surgical. AJR Am J Roentgenol. 199:W54–W64. 2012. View Article : Google Scholar : PubMed/NCBI
18	Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E and Detterbeck F: American College of Chest Physicians: Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 132((3 Suppl)): 178S–201S. 2007. View Article : Google Scholar : PubMed/NCBI
19	Mokhtar M, Kondo K, Takizawa H, Ohtani T, Otsuka H, Kubo H, Kajiura K, Nakagawa Y, Kawakami Y, Yoshida M, et al: Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [¹⁸F] FDG PET-CT. Oncol Rep. 31:2007–2014. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S and Yano S: Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 15:6630–6638. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, et al: mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 8:e621042013. View Article : Google Scholar : PubMed/NCBI
22	Nanjo S, Ebi H, Arai S, Takeuchi S, Yamada T, Mochizuki S, Okada Y, Nakada M, Murakami T and Yano S: High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget. 7:3847–3856. 2016. View Article : Google Scholar : PubMed/NCBI
23	Johnson DH, Schiller JH and Bunn PA Jr: Recent clinical advances in lung cancer management. J Clin Oncol. 32:973–982. 2014. View Article : Google Scholar : PubMed/NCBI
24	Noonan KL, Ho C, Laskin J and Murray N: The influence of the evolution of first-line chemotherapy on steadily improving survival in advanced non-small-cell lung cancer clinical trials. J Thorac Oncol. 10:1523–1531. 2015. View Article : Google Scholar : PubMed/NCBI